Penile Shortening After Prostate Surgery Temporary

Share this article:
Various treatments are available for post-prostatectomy erectile dysfunction.
By six months, the length returns to what it was before surgery.

Prostate cancer (PCa) patients undergoing radical prostatectomy may experience a small early loss of penile length after surgery, but this recovers by six months post-operatively, according to new findings. Use of a phosphodiesterase-5 inhibitor (PDE5i) attenuated SFPL loss, with patients who used PDE5i's regularly experiencing no loss in SFPL, researchers found.

In a study that included 118 men at baseline, a single evaluator measured stretched flaccid penile length (SFPL) before RP and again at two and six months after RP. At two and six months, 76 and 63 men, respectively, were evaluated. At two months post-surgery, patients had a mean 2.4 mm decrease in SFPL, but at six months, they observed no significant difference in SFPL from baseline overall, researchers led by John P. Mulhall, MD, of Memorial Sloan-Kettering Cancer Center in New York, reported online ahead of print in BJU International.

At six months, men who took a daily PDE5i had no SFPL loss, whereas those who did not take a PDE5i consistently had a significant mean 4.4 mm SFPL loss compared with baseline.

“The present study is among the first to show preservation of SFPL in patients using daily PDE5i as compared with those patients not using regular PDE5i,” the authors wrote.

Dr. Mulhall's group noted that multiple theories have been proposed for why penile length changes in the post-RP population. One hypothesis, the authors explained, is that “cavernous nerve injury results in sympathetic overdrive, causing smooth muscle contraction and a hypertonic retracted penis during the early phase.”

Share this article:
You must be a registered member of RUN to post a comment.
close

Next Article in Prostate Cancer

More in Prostate Cancer

Lower PSA Predicts Favorable Salvage Radiotherapy Outcomes

Lower PSA Predicts Favorable Salvage Radiotherapy Outcomes

Reduced likelihood of biochemical recurrence of prostate cancer also linked to concomitant hormonal therapy and positive surgical margins.

Assay May Prevent Unnecessary Repeat Prostate Biopsies

Assay May Prevent Unnecessary Repeat Prostate Biopsies

Epigenetic assay has a high negative predictive value for prostate cancer.

Prostate Cancer Patients Face Higher Risk of Second Malignancies

Prostate Cancer Patients Face Higher Risk of Second ...

Study reveals a 2-fold greater likelihood of primary kidney and bladder cancer compared with men in the general population.